TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1647685

Group type: EXPERIMENTAL
Intervention: Amino Acid Mix (AA mix)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Branched-Chain Amino Acids (BCAA)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both AA mix and BCAA
Number of subjects: 7
Study: 6196821

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage with 500,000 KIU aprotinin every 2 h
Number of subjects: 55

Group type: COMPARATOR
Intervention: Peritoneal lavage without aprotinin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 31411351

Group type: EXPERIMENTAL
Intervention: Low FI O2 (30% air-oxygen mixture)
Number of subjects: 86

Group type: COMPARATOR
Intervention: High FI O2 (100% oxygen during preoxygenation and recruitment maneuver, 60% air-oxygen mixture during mechanical ventilation)
Number of subjects: 86
Study: 30309382

Group type: EXPERIMENTAL
Intervention: Short Messaging Service (SMS) intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Non-SMS control group
Number of subjects: 104
Study: 26876911

Group type: EXPERIMENTAL
Intervention: Diet prime (cover of a dieting magazine) in Experiment 1
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Diet prime (diet-related commercials) in Experiment 2
Number of subjects: 701

Group type: COMPARATOR
Intervention: Control (no diet prime) in both experiments
Number of subjects: 701
Study: 25311633

Group type: COMPARATOR
Intervention: Chocolate consumption <1/month
Number of subjects: 20278

Group type: EXPERIMENTAL
Intervention: Chocolate consumption 1-3/week
Number of subjects: 20278

Group type: EXPERIMENTAL
Intervention: Chocolate consumption 2-4/week
Number of subjects: 20278

Group type: EXPERIMENTAL
Intervention: Chocolate consumption 5+/week
Number of subjects: 20278

Group type: EXPERIMENTAL
Intervention: Chocolate consumption 5+/week in men with BMI <25 kg/m2
Number of subjects: 20278

Group type: EXPERIMENTAL
Intervention: Chocolate consumption 5+/week in men with BMI 25+ kg/m2
Number of subjects: 20278
Study: 22075619

Group type: EXPERIMENTAL
Intervention: Three-dimensional computer model
Number of subjects: 40

Group type: COMPARATOR
Intervention: Two-dimensional images
Number of subjects: 40
Study: 21038647

Group type: EXPERIMENTAL
Intervention: Tongfu Granule (TFG), 1 bag, three times per day, for 7 days via oral intake or gastric infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, administered in the same manner as TFG
Number of subjects: 60
Study: 17665471

Group type: EXPERIMENTAL
Intervention: Arthritis Self-Help Course (ASHC)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Comparison between ASHC and CDSMP
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Both ASHC and CDSMP
Number of subjects: 416
Study: 16112071

Group type: EXPERIMENTAL
Intervention: Oral artemether (6 mg/kg) administered once every 2 weeks for 9-11 doses
Number of subjects: 783

Group type: COMPARATOR
Intervention: Placebo administered once every 2 weeks for 9-11 doses
Number of subjects: 783
Study: 12140351

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice a day)
Number of subjects: 140
Study: 10206298

Group type: COMPARATOR
Intervention: Cytokeratin 19 mRNA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cytokeratin 20 mRNA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Guanylyl cyclase C (GCC) mRNA
Number of subjects: 48
Study: 7750316

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg/kg bolus, continuous infusion at 2 micrograms/kg/min during surgery, and 30 mg nasogastric tube every 8 hours)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nontreated group (control)
Number of subjects: 23
Study: 2308471

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg O.D.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg B.I.D.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg O.D.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 381220

Group type: EXPERIMENTAL
Intervention: Pirbuterol 400 microgram
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microgram
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pirbuterol 200 microgram
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29316983

Group type: EXPERIMENTAL
Intervention: Urogenital schistosomiasis prevalence and intensity of S. haematobium infection evaluated microscopically by two filtrations of urine.
Number of subjects: 19039

Group type: EXPERIMENTAL
Intervention: Heavy infections of S. haematobium.
Number of subjects: 19039

Group type: EXPERIMENTAL
Intervention: Comparison of infection rates between males and females.
Number of subjects: 19039

Group type: EXPERIMENTAL
Intervention: Prevalence and intensity of infection in adolescents vs first-year students.
Number of subjects: 19039

Group type: EXPERIMENTAL
Intervention: Prevalence and intensity of infection in adults.
Number of subjects: 19039

Group type: EXPERIMENTAL
Intervention: Community knowledge about schistosomiasis.
Number of subjects: 19039

Group type: EXPERIMENTAL
Intervention: Risk behavior related to schistosomiasis.
Number of subjects: 19039
Study: 26720295

Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 282
Study: 25489844

Group type: EXPERIMENTAL
Intervention: Valganciclovir (valG) for 14 days pretransplant
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Valganciclovir (valG)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Valganciclovir (valG) and routine posttransplant viral prophylaxis
Number of subjects: 17
Study: 22950654

Group type: EXPERIMENTAL
Intervention: AZD7687 (5-60 mg, oral administration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20107765

Group type: EXPERIMENTAL
Intervention: Pmus(PVI)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Various methods of calculation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Assist levels (30%, 50%, 70%)
Number of subjects: 11
Study: 18854568

Group type: EXPERIMENTAL
Intervention: (90)Y‐ibritumomab tiuxetan consolidation
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: (90)Y‐ibritumomab tiuxetan
Number of subjects: 414

Group type: COMPARATOR
Intervention: No further treatment (control)
Number of subjects: 414
Study: 15698703

Group type: EXPERIMENTAL
Intervention: Method I (measuring the shortest distance between the posterior lip of the distal tibia and the talar dome)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other measurement techniques (not specified)
Number of subjects: 0
Study: 12699264

Group type: EXPERIMENTAL
Intervention: Postoperative medical therapy (progestins with or without estrogens)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppressing ovarian activity postoperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various drugs used before or after surgery
Number of subjects: 0
Study: 10760344

Group type: EXPERIMENTAL
Intervention: Shortened nitroglycerin HUT
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional nitroglycerin HUT
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Shortened nitroglycerin HUT (first test)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Shortened nitroglycerin HUT (second test)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control subjects (shortened nitroglycerin HUT)
Number of subjects: 137
Study: 8869864

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg twice daily (high dose)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Enalapril 5 mg twice daily (low dose)
Number of subjects: 83
Study: 1504052

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) with recombinant interferon-beta (IFN-beta)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Interleukin-2 (IL-2) without recombinant interferon-beta (IFN-beta)
Number of subjects: 49
Study: 6402342

Group type: EXPERIMENTAL
Intervention: Sustained-release buccal nitroglycerin (BNTG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30818032

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) plus Treatment as Usual (TAU)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study: 29324303

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (first-line)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Fulvestrant 250 mg (first-line)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (second-line)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Fulvestrant 250 mg (second-line)
Number of subjects: 730
Study: 27871510

Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg IV bolus)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal saline (IV bolus)
Number of subjects: 114
Study: 25050363

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-control of parafunctional habits (Control)
Number of subjects: 60
Study: 21471025

Group type: EXPERIMENTAL
Intervention: Fentanyl (1-2 μg/kg/h intravenously)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tramadol (0.1-0.2 mg/kg/h intravenously)
Number of subjects: 160
Study: 19852540

Group type: EXPERIMENTAL
Intervention: HBO2, 60 minutes of HBO(2) at 1.5 ATA
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NBH, 3 hours of 100% fraction of inspired oxygen at 1 ATA
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control, standard care
Number of subjects: 69
Study: 18395326

Group type: EXPERIMENTAL
Intervention: Once-daily vardenafil 10mg for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily vardenafil 10mg for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-demand vardenafil 10mg for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily vardenafil 10mg (12 weeks) vs On-demand vardenafil (24 weeks) after washout
Number of subjects: 0
Study: 16164192

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 22-Oxacalcitoriol (OCT)
Number of subjects: 10
Study: 14534517

Group type: EXPERIMENTAL
Intervention: Morphine (7.5 mg intravenous infusion over 3 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Quinidine (800 mg, placebo-controlled)
Number of subjects: 12
Study: 11406740

Group type: EXPERIMENTAL
Intervention: Oral enteric‐coated pamidronate (300 mg daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (3 g daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 12
Study: 9230826

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (6.0 MIU)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (1.5 MIU)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (3.0 MIU)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 8214412

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Alcohol (0.05 BAC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Alcohol (0.08 BAC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Alcohol (without sleep deprivation)
Number of subjects: 54
Study: 3624560

Group type: EXPERIMENTAL
Intervention: 3% butyl methoxydibenzoylmethane and 7% padimate O
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7% padimate O
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5% octyl salicylate and 3% oxybenzone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3% butyl methoxydibenzoylmethane alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7% padimate O alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 31724352

Group type: EXPERIMENTAL
Intervention: Needle-knife treatment, applied 1 time a week for 8 times, targeting specific anatomical points.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate, 0.2 g each time, 2 times daily for 4 weeks, total of 2 courses.
Number of subjects: 60
Study: 27521445

Group type: EXPERIMENTAL
Intervention: subunit cancer vaccine (recMAGE‐A3 protein+AS15)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: subunit cancer vaccine (recMAGE‐A3 protein+AS15) with intravesical BCG
Number of subjects: 24

Group type: COMPARATOR
Intervention: intravesical BCG
Number of subjects: 24
Study: 26039969

Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 28
Study: 23729804

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) withdrawal
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retreatment using other agents
Number of subjects: 45
Study: 20811901

Group type: EXPERIMENTAL
Intervention: DISE-TCI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional DISE
Number of subjects: 40
Study: 18989589

Group type: EXPERIMENTAL
Intervention: Immediate autologous bone graft combined with secondary dental implant
Number of subjects: 16

Group type: COMPARATOR
Intervention: Routine implantation without bone graft surgery
Number of subjects: 16
Study: 16536663

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 12749519

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg QD
Number of subjects: 5126

Group type: COMPARATOR
Intervention: Celecoxib 200 mg QD
Number of subjects: 5126
Study: 11023136

Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation intervention (40‐min nurse visit with counseling, education, and contracting)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care for diabetic smokers
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation intervention
Number of subjects: 280
Study: 9069573

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 879

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 879
Study: 8421118

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine toothpaste used 2x a day as a slurry rinse
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 14
Study: 31730601

Group type: EXPERIMENTAL
Intervention: Phase 1 clinical trial participation
Number of subjects: 30
Study: 28891445

Group type: EXPERIMENTAL
Intervention: Formal diagnosis of dementia
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Anti-dementia drug treatment
Number of subjects: 319

Group type: COMPARATOR
Intervention: Depression (Geriatric Depression Scale; GDS)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Quality of life in Alzheimer's disease (Qol-AD)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Knowledge about dementia
Number of subjects: 319
Study: 26758039

Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone followed by a 25-month course of oral prednisolone (P group, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined with mizoribine (150 mg/day for 24 months, M + P group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study: 25189430

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg oral tablet one hour before surgery, plus 0.2 mg·day(‐1) transdermal patch placed one hour before surgery and removed four days after surgery or hospital discharge)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Clonidine and Placebo (combined outcomes)
Number of subjects: 168
Study: 22329667

Group type: EXPERIMENTAL
Intervention: HA-coated components
Number of subjects: 68

Group type: COMPARATOR
Intervention: Uncoated components
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cemented components
Number of subjects: 68
Study: 21129211

Group type: EXPERIMENTAL
Intervention: PALM PLUS intervention (integrated guideline and training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PALM PLUS intervention
Number of subjects: 30
Study: 17679361

Group type: EXPERIMENTAL
Intervention: Melatonin, 5 mg daily for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with Epigastric Pain Syndrome (before treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with Postprandial Disorders Syndrome (before treatment)
Number of subjects: 60
Study: 16120036

Group type: EXPERIMENTAL
Intervention: NovoPen 3
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FlexPen
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NovoPen 3 and FlexPen
Number of subjects: 48
Study: 12377205

Group type: EXPERIMENTAL
Intervention: Preservation of the great auricular nerve (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sacrificing the great auricular nerve (group B)
Number of subjects: 24
Study: 10541775

Group type: EXPERIMENTAL
Intervention: Repro-Dose morphine (RDM) once daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: MST Continuous (MST) twice daily
Number of subjects: 47
Study: 7776913

Group type: EXPERIMENTAL
Intervention: Pamphlet with brief advice
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Group dietary counselling
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Individual counselling
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Dietitian-based counselling
Number of subjects: 131
Study: 2187009

Group type: EXPERIMENTAL
Intervention: fenfluramine treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 7
Study: 89278

Group type: EXPERIMENTAL
Intervention: Prolonged breast-feeding (more than 6 months)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Breast-feeding for 2–6 months
Number of subjects: 236

Group type: COMPARATOR
Intervention: Weaning to cow's-milk-based formulas at less than 2 months
Number of subjects: 236
Study: 30468936

Group type: EXPERIMENTAL
Intervention: Immunomodulating enteral nutrition (IMPACT group; IG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard enteral nutrition (Ensure group; EG)
Number of subjects: 40
Study: 29730280

Group type: EXPERIMENTAL
Intervention: Multicriteria optimization database (MCOD)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Clinical plan database (CPD)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Replans using KBP predictions
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: KBP predictions
Number of subjects: 124
Study: 27066188

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei (4 × 10(8) CFU) with prebiotic Inulin (400 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no synbiotic supplementation)
Number of subjects: 32
Study: 24553574

Group type: EXPERIMENTAL
Intervention: High dose ethanol
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Low dose ethanol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 22682276

Group type: EXPERIMENTAL
Intervention: Provider malaria training intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider malaria training intervention plus school-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined provider plus school-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expected standard practice in malaria diagnosis and treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider intervention alone
Number of subjects: 0
Study: 21060104

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (starting at 2000 mg/d)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Azathioprine (starting at 2 mg/kg/d)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 156
Study: 17996511

Group type: EXPERIMENTAL
Intervention: losartan 100 mg
Number of subjects: 24
Study: 15743365

Group type: EXPERIMENTAL
Intervention: Dexloxiglumide 200 mg t.i.d. for 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12038783

Group type: EXPERIMENTAL
Intervention: Single doses of tinzaparin (175 IU/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Single doses of tinzaparin (75 IU/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tinzaparin (weight-adjusted dosing)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 37
Study: 9696214

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Ovulation Induction
Number of subjects: 815
Study: 8570785

Group type: EXPERIMENTAL
Intervention: Eye movements only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous eye and rapid arm movements toward the target
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous eye and arm movements with a restraint blocking the arm
Number of subjects: 0
Study: 2763876

Group type: EXPERIMENTAL
Intervention: High dietary calcium intake (1752 mg elemental Ca per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low dietary calcium intake (391 mg elemental Ca per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium infusion (2 mg Ca per kg body weight over 5 minutes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral calcium load (500 mg as CaCO3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcium supplements (1500 mg Ca per day as CaCO3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-Ca diet (approximately 400 mg Ca per day)
Number of subjects: 10
Study: 7174

Group type: EXPERIMENTAL
Intervention: Carbuterol 200 mug 4 times per day for 6 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isoproterenol 150 mug 4 times per day for 6 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High dose aerosolized carbuterol
Number of subjects: 46

Group type: COMPARATOR
Intervention: High dose aerosolized isoproterenol
Number of subjects: 46
Study: 30323359

Group type: EXPERIMENTAL
Intervention: 8IU intranasal oxytocin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 24IU intranasal oxytocin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IV oxytocin
Number of subjects: 16